Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Peterlabs Holdings Bhd's enterprise value is RM71.8 Mil.
Peterlabs Holdings Bhd's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was RM1.7 Mil. Therefore, Peterlabs Holdings Bhd's EV-to-EBITDA for today is 42.37.
The historical rank and industry rank for Peterlabs Holdings Bhd's EV-to-EBITDA or its related term are showing as below:
XKLS:0171's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 13.08 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Peterlabs Holdings Bhd (XKLS:0171) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Peterlabs Holdings Bhd's PE Ratio (TTM) for today is calculated as:
Peterlabs Holdings Bhd's share price for today is RM0.23.
Peterlabs Holdings Bhd's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0171 vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's EV-to-EBITDA falls into.
Peterlabs Holdings Bhd's current Enterprise Value is RM71.8 Mil.
Peterlabs Holdings Bhd's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was RM1.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a EV-to-EBITDA of 42.37 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Peterlabs Holdings Bhd.
Is Peterlabs Holdings Bhd's EV-to-EBITDA too high?
Peterlabs Holdings Bhd's current EV-to-EBITDA is 42.37. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. Peterlabs Holdings Bhd's value of 42.37 is 223.9% above this industry median. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's EV-to-EBITDA compare to ZTS and UTHR?
Peterlabs Holdings Bhd's EV-to-EBITDA of 42.37 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 13.08. Peterlabs Holdings Bhd's value of 42.37 is 223.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current EV-to-EBITDA of 42.37 is 223.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Peterlabs Holdings Bhd. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current EV-to-EBITDA is 42.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current EV-to-EBITDA of 42.37. The current EV-to-EBITDA is 42.37 and 223.9% above the Drug Manufacturers industry median of 13.08. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current EV-to-EBITDA is 42.37 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
